Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DDS stock price vs CRM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CRM's multiple
Needs CRM P/E.
Implied fair value · at DDS's multiple
Needs DDS P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DDS FY 2026 (ended Jan 31, 2026) · CRM FY 2026 (ended Jan 31, 2026).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
DILLARD’S, INC. · implied price per share
Bear
$207.26K
Base
$243.84K
Bull
$280.42K
Salesforce, Inc. · implied price per share
Bear
$71.92
Base
$84.61
Bull
$97.30
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.30x
0.31x
Net debt / EBITDA
Leverage against operating earnings
-0.48x
0.90x
Cash and equivalents
Liquid reserves on the balance sheet
$861.46M
$9.31B
Total debt
Interest-bearing obligations outstanding
$526.64M
$18.44B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe DDS can reaccelerate growth and maintain its margin profile despite the -0.4% revenue growth, then DDS can be attractive on a P/E basis because it trades at 16.2x versus CRM at 23.6x; otherwise, the premium quality and growth of CRM justify most of the relative valuation gap.
DDS trades at 16.2x P/E versus CRM at 23.6x, so it is cheaper on earnings despite the model implying 46.0% upside to $859.23. However, the provided CRM-implied, historical band, and DCF ranges are internally inconsistent and extremely wide, which lowers confidence in the valuation signal.
Supporting Metrics
Live quote
